Potential nonhormonal therapeutics for medical treatment of leiomyomas

Steven L. Young, Ayman Al-Hendy, John A. Copland

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Uterine leiomyomas are a common disorder resulting in significant morbidity for women and substantial economic impact on the health care system. Current therapies include conservative surgery, hysterectomy, and hormonal therapy. Conservative surgical therapy often fails because of recurrence, and hysterectomy dramatically limits reproductive options. Radiologic therapies are associated with considerable risk of morbidity and mortality and are not likely to be compatible with reproduction. Hormonal therapies such as gonadotropin-releasing hormone (GnRH) analogues or progestins with or without estrogen are utilized by many patients, but long-term use of either is often responsible for unacceptable morbidity and hormonal therapies are not compatible with reproduction. Newer hormonal alternatives such as progesterone antagonists and selective agonists as well as "add-back" estrogen therapy in addition to GnRH analogues have been developed and show promise. However, no hormonal therapy that significantly alters estrogen and progesterone production or function is likely to be compatible with reproduction. Thus, it is important to develop novel nonhormonal therapies for medical treatment of leiomyomas. Other laboratories have evaluated pirfenidone, halofuginone, heparin, and interferon-α (IFN-α). Recent work in our laboratory suggests potential use of two additional classes of compounds, thiazolidinediones and tocopherol analogs. The rationale, evidence, and potential for the use of each of these compounds in the treatment of leiomyomas are discussed.

Original languageEnglish (US)
Pages (from-to)121-130
Number of pages10
JournalSeminars in Reproductive Medicine
Volume22
Issue number2
DOIs
StatePublished - May 1 2004

Fingerprint

Leiomyoma
Reproduction
Estrogens
Therapeutics
Morbidity
Hysterectomy
Gonadotropin-Releasing Hormone
Progesterone
Progesterone Congeners
Thiazolidinediones
Tocopherols
Interferons
Heparin
Economics
Delivery of Health Care
Recurrence
Mortality

Keywords

  • Alpha-tocopherol succinate
  • Apoptosis
  • Leiomyoma
  • Thiazolidinedione
  • Tocopherol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)

Cite this

Potential nonhormonal therapeutics for medical treatment of leiomyomas. / Young, Steven L.; Al-Hendy, Ayman; Copland, John A.

In: Seminars in Reproductive Medicine, Vol. 22, No. 2, 01.05.2004, p. 121-130.

Research output: Contribution to journalReview article

Young, Steven L. ; Al-Hendy, Ayman ; Copland, John A. / Potential nonhormonal therapeutics for medical treatment of leiomyomas. In: Seminars in Reproductive Medicine. 2004 ; Vol. 22, No. 2. pp. 121-130.
@article{671595e84560449095914f9d082c855f,
title = "Potential nonhormonal therapeutics for medical treatment of leiomyomas",
abstract = "Uterine leiomyomas are a common disorder resulting in significant morbidity for women and substantial economic impact on the health care system. Current therapies include conservative surgery, hysterectomy, and hormonal therapy. Conservative surgical therapy often fails because of recurrence, and hysterectomy dramatically limits reproductive options. Radiologic therapies are associated with considerable risk of morbidity and mortality and are not likely to be compatible with reproduction. Hormonal therapies such as gonadotropin-releasing hormone (GnRH) analogues or progestins with or without estrogen are utilized by many patients, but long-term use of either is often responsible for unacceptable morbidity and hormonal therapies are not compatible with reproduction. Newer hormonal alternatives such as progesterone antagonists and selective agonists as well as {"}add-back{"} estrogen therapy in addition to GnRH analogues have been developed and show promise. However, no hormonal therapy that significantly alters estrogen and progesterone production or function is likely to be compatible with reproduction. Thus, it is important to develop novel nonhormonal therapies for medical treatment of leiomyomas. Other laboratories have evaluated pirfenidone, halofuginone, heparin, and interferon-α (IFN-α). Recent work in our laboratory suggests potential use of two additional classes of compounds, thiazolidinediones and tocopherol analogs. The rationale, evidence, and potential for the use of each of these compounds in the treatment of leiomyomas are discussed.",
keywords = "Alpha-tocopherol succinate, Apoptosis, Leiomyoma, Thiazolidinedione, Tocopherol",
author = "Young, {Steven L.} and Ayman Al-Hendy and Copland, {John A.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1055/s-2004-828618",
language = "English (US)",
volume = "22",
pages = "121--130",
journal = "Seminars in Reproductive Medicine",
issn = "1526-8004",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Potential nonhormonal therapeutics for medical treatment of leiomyomas

AU - Young, Steven L.

AU - Al-Hendy, Ayman

AU - Copland, John A.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Uterine leiomyomas are a common disorder resulting in significant morbidity for women and substantial economic impact on the health care system. Current therapies include conservative surgery, hysterectomy, and hormonal therapy. Conservative surgical therapy often fails because of recurrence, and hysterectomy dramatically limits reproductive options. Radiologic therapies are associated with considerable risk of morbidity and mortality and are not likely to be compatible with reproduction. Hormonal therapies such as gonadotropin-releasing hormone (GnRH) analogues or progestins with or without estrogen are utilized by many patients, but long-term use of either is often responsible for unacceptable morbidity and hormonal therapies are not compatible with reproduction. Newer hormonal alternatives such as progesterone antagonists and selective agonists as well as "add-back" estrogen therapy in addition to GnRH analogues have been developed and show promise. However, no hormonal therapy that significantly alters estrogen and progesterone production or function is likely to be compatible with reproduction. Thus, it is important to develop novel nonhormonal therapies for medical treatment of leiomyomas. Other laboratories have evaluated pirfenidone, halofuginone, heparin, and interferon-α (IFN-α). Recent work in our laboratory suggests potential use of two additional classes of compounds, thiazolidinediones and tocopherol analogs. The rationale, evidence, and potential for the use of each of these compounds in the treatment of leiomyomas are discussed.

AB - Uterine leiomyomas are a common disorder resulting in significant morbidity for women and substantial economic impact on the health care system. Current therapies include conservative surgery, hysterectomy, and hormonal therapy. Conservative surgical therapy often fails because of recurrence, and hysterectomy dramatically limits reproductive options. Radiologic therapies are associated with considerable risk of morbidity and mortality and are not likely to be compatible with reproduction. Hormonal therapies such as gonadotropin-releasing hormone (GnRH) analogues or progestins with or without estrogen are utilized by many patients, but long-term use of either is often responsible for unacceptable morbidity and hormonal therapies are not compatible with reproduction. Newer hormonal alternatives such as progesterone antagonists and selective agonists as well as "add-back" estrogen therapy in addition to GnRH analogues have been developed and show promise. However, no hormonal therapy that significantly alters estrogen and progesterone production or function is likely to be compatible with reproduction. Thus, it is important to develop novel nonhormonal therapies for medical treatment of leiomyomas. Other laboratories have evaluated pirfenidone, halofuginone, heparin, and interferon-α (IFN-α). Recent work in our laboratory suggests potential use of two additional classes of compounds, thiazolidinediones and tocopherol analogs. The rationale, evidence, and potential for the use of each of these compounds in the treatment of leiomyomas are discussed.

KW - Alpha-tocopherol succinate

KW - Apoptosis

KW - Leiomyoma

KW - Thiazolidinedione

KW - Tocopherol

UR - http://www.scopus.com/inward/record.url?scp=2542503396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542503396&partnerID=8YFLogxK

U2 - 10.1055/s-2004-828618

DO - 10.1055/s-2004-828618

M3 - Review article

C2 - 15164307

AN - SCOPUS:2542503396

VL - 22

SP - 121

EP - 130

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

SN - 1526-8004

IS - 2

ER -